A Simplified Method for the Clinical-scale Generation of Central Memory-like CD8+ T Cells After Transduction With Lentiviral Vectors Encoding Antitumor Antigen T-cell Receptors
暂无分享,去创建一个
Richard A. Morgan | Steven A. Rosenberg | S. Rosenberg | R. Morgan | M. Dudley | Shicheng Yang | Mark E. Dudley | Shicheng Yang
[1] A. Nel,et al. Response differences between human CD4(+) and CD8(+) T-cells during CD28 costimulation: implications for immune cell-based therapies and studies related to the expansion of double-positive T-cells during aging. , 2000, Clinical Immunology.
[2] D. Srivastava,et al. Infusion of Cytotoxic T Cells for the Prevention and Treatment of Epstein-Barr Virus–Induced Lymphoma in Allogeneic Transplant Recipients , 1998 .
[3] T. Waldmann,et al. Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[4] E. Lam,et al. Commitment Point during G0→G1 That Controls Entry into the Cell Cycle , 2003, Molecular and Cellular Biology.
[5] Clelia Di Serio,et al. Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration , 2006, Nature Biotechnology.
[6] F. Gage,et al. In Vivo Gene Delivery and Stable Transduction of Nondividing Cells by a Lentiviral Vector , 1996, Science.
[7] D. Srivastava,et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. , 1998, Blood.
[8] S. Rosenberg,et al. Tumor-specific cytolysis by lymphocytes infiltrating human melanomas. , 1989, Journal of immunology.
[9] S. Rosenberg,et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] S. Rosenberg,et al. CD8+ T Cell Immunity Against a Tumor/Self-Antigen Is Augmented by CD4+ T Helper Cells and Hindered by Naturally Occurring T Regulatory Cells , 2005, The Journal of Immunology.
[11] S. Rosenberg,et al. Gene Transfer of Tumor-Reactive TCR Confers Both High Avidity and Tumor Reactivity to Nonreactive Peripheral Blood Mononuclear Cells and Tumor-Infiltrating Lymphocytes1 , 2006, The Journal of Immunology.
[12] S. Riddell,et al. The use of anti-CD3 and anti-CD28 monoclonal antibodies to clone and expand human antigen-specific T cells. , 1990, Journal of immunological methods.
[13] S. Rosenberg,et al. Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes , 2006, Science.
[14] Mike Gough,et al. Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. , 2008, The Journal of clinical investigation.
[15] S. Riddell,et al. Phase I Study of Cellular Adoptive Immunotherapy Using Genetically Modified CD8+ HIV-Specific T Cells for HIV Seropositive Patients Undergoing Allogeneic Bone Marrow Transplant. Fred Hutchinson Cancer Research Center and the University of Washington , 1992 .
[16] S. Riddell,et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. , 1995, The New England journal of medicine.
[17] S. Rosenberg,et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. , 2009, Blood.
[18] S. Rosenberg,et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] H. von Boehmer,et al. The impact of CD4+CD25+ Treg on tumor specific CD8+ T cell cytotoxicity and cancer. , 2006, Seminars in cancer biology.
[20] P. Kourilsky,et al. Lineage relationships, homeostasis, and recall capacities of central– and effector–memory CD8 T cells in vivo , 2005, The Journal of experimental medicine.
[21] S. Rosenberg,et al. Clinical-scale Lentiviral Vector Transduction of PBL for TCR Gene Therapy and Potential for Expression in Less-differentiated Cells , 2008, Journal of immunotherapy.
[22] S. Rosenberg,et al. Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. , 2005, The Journal of clinical investigation.
[23] S. Seki,et al. Systematic characterization of human CD8+ T cells with natural killer cell markers in comparison with natural killer cells and normal CD8+ T cells , 2001, Immunology.
[24] M. Merino,et al. FOXP3 expression accurately defines the population of intratumoral regulatory T cells that selectively accumulate in metastatic melanoma lesions. , 2008, Blood.
[25] S. Rosenberg,et al. Development of optimal bicistronic lentiviral vectors facilitates high-level TCR gene expression and robust tumor cell recognition , 2008, Gene Therapy.
[26] S. Rosenberg,et al. Lentiviral vector design for optimal T cell receptor gene expression in the transduction of peripheral blood lymphocytes and tumor-infiltrating lymphocytes. , 2009, Human gene therapy.
[27] Steven A. Rosenberg,et al. Generation of Tumor-Infiltrating Lymphocyte Cultures for Use in Adoptive Transfer Therapy for Melanoma Patients , 2003, Journal of immunotherapy.
[28] A. Schambach,et al. Woodchuck hepatitis virus post-transcriptional regulatory element deleted from X protein and promoter sequences enhances retroviral vector titer and expression , 2006, Gene Therapy.
[29] C. June,et al. 4-1BB Is Superior to CD28 Costimulation for Generating CD8+ Cytotoxic Lymphocytes for Adoptive Immunotherapy1 , 2007, The Journal of Immunology.
[30] Fumito Ito,et al. Antitumor Reactivity of Anti-CD3/Anti-CD28 Bead-Activated Lymphoid Cells: Implications for Cell Therapy in a Murine Model , 2003, Journal of immunotherapy.
[31] John R. Mascola,et al. Gene transfer in humans using a conditionally replicating lentiviral vector , 2006, Proceedings of the National Academy of Sciences.
[32] C. June,et al. Engineering artificial antigen-presenting cells to express a diverse array of co-stimulatory molecules. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.